Biognosys

Blue Sky BioServices, founded in 2003 to serve the Boston area life sciences research hub, is the leading Contract Research Organization (CRO) providing R&D based Gene through Screen services for biotech and pharma companies from startups to established leaders in the field. Our customers enhance the quality and speed of their research by partnering with Blue Sky to receive world class services including; gene synthesis and bulk plasmid preparations, antibody cloning, scale-up production of recombinant proteins in multiple cell lines including mammalian, insect, bacterial and yeast, as well as antibody/protein purification and robust, rapid assay services such as cytotoxicity and qPCR, MSD. Our Assay team can support many commercially available screening technology in 96 and 384-well formats (fluorescent, colorimetric, etc.). Ultimately, we want to run YOUR assay, YOUR way. We will build out additional capabilities and capacity to support your screening workflow.

Blue Sky differentiates itself with its team of experienced scientists, leading edge process technology, and state-of-the-art laboratory facilities. Our commitment to scientific expertise and value has transformed the company into a center of excellence with unmatched quality and turnaround times.

We are motivated by ensuring our customers have an excellent experience working with Blue Sky. We do that by delivering projects on time, with high quality, at competitive prices, led by our team of highly skilled, energetic and collaborative scientists.

Groken Bioscience was found in September 2014 and based in Hong Kong. Our founders and technical board have many years of experience in genomics research and development. The vision of Groken Bioscience is dedicated to improve the healthcare of mankind by utilizing genomics information. We are the first Hong Kong based integrated genomic service provider to introduce the latest genomic research platforms into Hong Kong. Also, we are the first in Asia and China, using big data on microbiome genomics, to provide a tool for individuals to discover their microbiome for health management.

Groken Bioscience has three ambitious missions:

1. Provide Most Advanced Genomics Technologies Service for Researchers
Utilizing state of art next generation sequencing platform such as Illumina HiSeq X, HiSeq2500/2000, NextSeq 500, Miseq and third generation sequencing platform such as PacBio, we are dedicated to facilitate collaborative research and providing the highest quality sequencing service and customized bioinformatics analysis to academics, pharmaceuticals and clinical communities.

2. Develop Cutting Edge Healthcare Management Technologies
We will establish our own R&D laboratory in the Hong Kong Science Park. The laboratory will act as a platform to develop advance technologies and transfer genomic science to quality products or service. We also dedicated to create an ecosystem for high quality genetic services to be delivered from research developers to service providers to health aware consumers through a healthcare management web portal system which can provide business-to-business channels, business-to-consumers healthcare report interface, consumers-to-consumers social networking and Online-to-Offline service delivery.

3. Enhance Research Collaborations
We also serves as a hub for collaborative research. With our team of molecular biologists and bioinformaticians, we aim to collaborate and work with different researchers to advance genomic science.

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging

Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications.

We provide:

- Classical and proprietary diet-induced in vivo models
- Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, …)
- In vivo preclinical imaging services

Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.

Strand Life Sciences is a Bangalore-based bioinformatics company founded in 2000 by entrepreneurs from the Indian Institute of Science. Strand’s mission is to support precision medicine across the entire R&D lifecycle, from the lab to the clinic to data analysis. To that end, Strand has developed tools, platforms and services that span these disciplines. Key achievements include a cutting edge NGS liquid biopsy assay for early detection of oral cancer from saliva; a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials; a CAP and NABL-accredited genomics lab that has tested ≈10,000 samples in oncology, germline cancer, and rare diseases; Strand NGS, a software platform for secondary and tertiary analysis of NGS data; StrandOmics, a HIPAA-compliant, cloud-based platform for germline and somatic variant interpretation and reporting, used to generate clinical reports on all the ≈10,000 samples tested in our labs; and StrandIris, a fully automated, HIPAA-compliant cloud solution for interpretation and reporting of somatic variants. Underpinning these achievements is a strong track record of delivery on software development, assay development and biomarker studies projects with leading US-based instrument, diagnostics, pharmaceutical and biotech companies, a customer-base spanning ≈200 academics and diagnostics companies, and ≈25,000 citations of products developed at Strand since 2005.